Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors

“Therapeutic targets are only found in a small percentage of all the patients. It’s not like half of them will have target X. But if you don't test, you're potentially denying the patient access to a drug or a trial for their specific tumor biology. That’s an important message to get out there.”

CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) macrophage therapy by Carisma Therapeutics is being evaluated in a phase 1, first-in-human study (NCT04660929) for safety and tolerability in solid tumors with HER2 overexpression.

Data seen so far from the study were presented at the 2022 American Society of Clinical Oncology (ASCO) meeting, held June 3-7, 2022, held both virtually and in Chicago, Illinois by Kim A. Reiss Binder, MD, assistant program director, Hematology/Oncology Fellowship Program, and assistant professor of medicine, University of Pennsylvania Hospital.

CGTLive spoke to Binder to learn more about the progress of the study and the potential of CAR macrophages in solid tumors. She stressed the importance of testing tumors for genetic markers for targeted therapies.

REFERENCE

Reiss KA, Yuan Y, Ueno NT, et al. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. Presented at: 2022 ASCO Meeting, June 3-7; Chicago, IL. Abstract # 2533